Medicines quality assurance: WHO normative functions in the field of pharmaceuticals Sabine Kopp, PhD Quality Assurance and Safety: Medicines Department.

Slides:



Advertisements
Similar presentations
Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Advertisements

Prequalification of HIV/AIDS Drugs - UN joint activity lPartners* –UNAIDS –UNICEF –UNFPA –WHO –With the support of World Bank lWHO –Manages, provides technical.
Drug regulation and quality assurance: WHO normative functions in the field of pharmaceuticals Technical Briefing Seminar 19 September 2006 Sabine Kopp,
1 Technical Briefing Seminar | 1 November 2012 Safe quality medicines.
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
WHO STRATEGY FOR WORKING WITH COUNTRIES:REGIONAL AND COUNTRY PERSPECTIVE TECHNICAL BRIEFING SEMINAR,Geneva,19-23 September 2005 Dr. Jean-Marie TRAPSIDA.
1 WHOs Role in Assuring the Quality Safety and Efficacy of Drugs: Introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines.
WHOs Normative Work in the Field of Pharmaceuticals - introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines Essential.
WHO update on: Guidelines for the selection of RH medicines and prequalification of priority RH medicines Medicines Policy and Standards Health Technology.
WHO and its activities in quality assurance of medicines Sabine Kopp, PhD Quality Assurance and Safety: Medicines Essential Drugs and Medicines Policy.
3rd WHO Prequalification Stakeholders Meeting
WHO Training Course on Prequalification Introduction Efficacy and Safety Issues Hans Kemmler Consultant to WHO Accra, 5.Nov
UNICEF Medicines Supply Strengthening WHO Technical Briefing Seminar on Essential Medicines and Health Products Tuesday 29 October 2013 Technical Specialist.
1 Dr S. Kopp WHO's normative functions in the field of pharmaceuticals WHO Expert Committee on Specifications for Pharmaceutical Preparations Secretary:
IPC meeting June 2014 Dr Joelle DAVIAUD, Quality Assurance Specialist Model Quality Assurance System for procurement agencies.
Update to IPC on MODEL QUALITY ASSURANCE SYSTEM FOR PROCUREMENT AGENCIES (MQAS) Dr Sabine Kopp 16 December 2014 Update to IPC on MODEL QUALITY ASSURANCE.
Presentation 4.2 CODEX STANDARDS ON SAFETY Section IV Food Quality and Standards Service (ESNS) Food and Nutrition Division. FAO.
ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
The Quality Management System
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
Update on prequalification of essential medicines for reproductive health Dr Hans V. Hogerzeil Director Medicines Policy and Standards WHO, Geneva Reproductive.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
ACADs (08-006) Covered Keywords Commission, regulation, advisory, standards. Description This presentation provides general information about each of the.
Wilbert Bannenberg SARPAM
Bioequivalence and Bioavailability Working Group.
The International Pharmacopoeia Overview Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines Quality of Active Pharmaceutical Ingredients,
QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.
And Pharmaceuticals Health Technology Technical Cooperation for Essential Drugs and Traditional Medicine Challenges of Medicine Regulation in Africa Global.
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
1 WH O Technical Briefing | September 2010 Safe quality medicines.
The Codex Alimentarius Commission
WHO support to countries in the area of medicines example of the African Region WHO/EDM Drug Action Programme.
1 WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Tuesday 1 November 2011 Technical Specialist Henrik K.Nielsen, Medicines and Nutrition.
Slide 1 of 10D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
WHO Prequalification of Medicines Programme Raul Kiivet, MD, PhD Manager, Prequalification of Medicines Programme Quality Assurance and Safety: Medicines.
1 SUPPLY DIVISION Procurement and Supply Management Technical Assistance.
The International Pharmacopoeia Overview Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines Quality of Active Pharmaceutical Ingredients,
Drug regulation and quality assurance: WHO normative functions in the field of pharmaceuticals Sabine Kopp, PhD Quality Assurance and Safety: Medicines.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
WHO Prequalification Programme Milan Smid, M.D., Ph.D. Prequalification Programme: Priority Essential Medicines.
UNICEF Medicines Supply Strengthening WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Tuesday 30 October 2012 Technical Specialist.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
The WHO Prequalification of Medicines Program - Introduction Tony Gould Manager, Prequalification of Medicines Program WHO.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.
Leveraging the prequalification process for national regulatory decision making Fimbo, A. M Tanzania Food and Drugs Authority.
2010 James Fitzgerald Senior Advisor, Medicines and Health Technologies PAHO/WHO rd St Washington DC USA International Cooperation in Quality.
Implementation of PANDRH Guidelines NAFTA Region VI PANDRH Conference Brasilia, July 2-8, 2011 Justina Molzon -- US Food and Drug Administration Mike Ward.
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
1 WH O Technical Briefing | September 2011 Safe quality medicines.
WHO Technical Briefing Seminar
Overview of the EAC Pharmacovigilance and Post-Marketing Surveillance Systems 1ST International High Level Multi-Stakeholder Conference Nairobi, 2-4.
Medicines quality assurance:
The Codex Alimentarius Commission
Wilbert Bannenberg SARPAM
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
Safe quality medicines
The WHO Prequalification of Medicines Programme Capacity building agenda Dr Milan Smid.
Overview of vaccines prequalification
FAO/WHO CODEX TRAINING PACKAGE
World Health Organization
Quality Problems with Antimalarials
Drug regulation and quality assurance:
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Prequalification Programme of Medicines (PQP): Introductory messages
Prequalification of HIV/AIDS products and manufacturers
Presentation transcript:

Medicines quality assurance: WHO normative functions in the field of pharmaceuticals Sabine Kopp, PhD Quality Assurance and Safety: Medicines Department of Medicines Policy and Standards

2QC L Training Seminar, Tanzania | 5-7 December 2007 Main points addressed n WHO role and function n WHO standard setting process n WHO international guidelines, standards and norms in the area of quality assurance n WHO's operational strategies

3QC L Training Seminar, Tanzania | 5-7 December 2007 WHO does the work? n 193 Member States n Two governing bodies: - World Health Assembly - Executive Board n WHO Secretariat: - HQ - six Regional Offices and Country offices - WHO Expert Panels and Expert Committees (e.g... on the International Pharmacopoeia and Pharmaceutical Preparations) Constitution 1946, in force since 7 April 1948 (World Health Day)

4QC L Training Seminar, Tanzania | 5-7 December 2007 How to become a "WHO Expert"? n Official nomination process n Upon proposal to WHO in consultation with: l Member State/national government (citizenship)+ l WHO Regional Office (in accordance with Member State) + l WHO Headquarters n Period of maximum 4 years n Possibility to renew

5QC L Training Seminar, Tanzania | 5-7 December 2007 What is the WHO Expert Committee? n Official Advisory Body to Director-General of WHO n Governed though rules and procedures (Ref. WHO Manual) n Participation in Expert Committee (EC) meetings: ä Members ("Expert") selected from WHO Panel of Experts ä Technical advisers ä Observers: - international organizations, - NGOs, - professional associations…

6QC L Training Seminar, Tanzania | 5-7 December 2007 Outcome of the WHO Expert Committee? n Report of the WHO Expert Committee: - Summarizes discussion - Gives recommendations to WHO + Member States - Includes newly adopted guidelines; - Is presented to WHO Governing Bodies for final comments, endorsement and implementation by Member States n  constitutes WHO technical guidance

7QC L Training Seminar, Tanzania | 5-7 December 2007 Examples of WHO Expert Committees ? n WHO Expert Committee on Specifications for Pharmaceutical Preparations n WHO Expert Committee on the Selection and Use of Essential Medicines n WHO Expert Committee on Drug Dependence n WHO Expert Committee on Biological Standardization n Joint FAO/WHO Expert Committee on Food Additives n ….

8QC L Training Seminar, Tanzania | 5-7 December 2007 How does the WHO consultation process work? n Step 1. Preliminary consultation and drafting n Step 2. Draft guidelines n Step 3. Circulation for comments n Step 4. Revision process n (back to step 2 and 3 as often as needed) n  WHO Expert Committee (EC) meeting ä  if guideline adopted, published in EC report as Annex n -> WHO Governing bodies n -> Recommendation to Member States for implementation

9QC L Training Seminar, Tanzania | 5-7 December 2007 WHO Partners n National and regional authorities n International organizations (UNAIDS, UNFPA, UNICEF, World Bank, WIPO, WTO, WCO, etc) n International professional and other associations, NGOs (including consumer associations, MSF, industry: IFPMA-IGPA- WSMI, FIP, WMA, etc) n WHO Expert Panels (official nomination process) n Specialists from all areas, regulatory, university, industry……… n WHO Collaborating Centres (official nomination process) n Pharmacopoeia Commissions and Secretariats, national institutions and institutes.. n Regional and inter-regional groups (ICH…)

10Q CL Training Seminar, Tanzania | 5-7 December 2007 Why need for stringent standards for medicines? "… drugs are a public good and not simply just another commodity: first for their high social value, and then because consumers and prescribers are unable to assess their quality, safety and efficacy" (Dr Gro Harlem Brundtland, former Director General of the World Health Organization) n  medicines belong to one of the most regulated group of products

11Q CL Training Seminar, Tanzania | 5-7 December 2007 Medicines Quality Assurance in WHO Historical overview  1874Discussion on Unification of terminology and composition of drugs  1902 First Conference organized by Belgian Government  1906Agreement on Unification of the Formulae of Potent Drugs ratified by 19 states  1925 Brussels agreement (signed 1929)  League of Nations: “international pharmacopoeia”

12Q CL Training Seminar, Tanzania | 5-7 December 2007 Medicines Quality Assurance in WHO Historical overview (2)  1937 First meeting (experts from B, DK, F, NL, CH, UK, USA) - League of Nations  1947 Interim Commission of WHO takes up health related work of League of Nations  1948 First World Health Assembly established Expert Committee on Unification of Pharmacopoeia

13Q CL Training Seminar, Tanzania | 5-7 December 2007 Challenges: past and present… n Past: ä Manufacture direct from API -> finished product ä Manufacture of API in sites close to or same as product ä Experience and long-standing knowledge of production, product and manufacture of parties involved ä Few intermediates in sales chain ä Usually stable trade and sales connections

14Q CL Training Seminar, Tanzania | 5-7 December 2007 Challenges: past and present… n Present: ä Rationalization of drug production ä Contracting-out of many steps in manufacture ä Many intermediates in trade and sales chain ä Trade, shipping, long distances involved ä Increase of risks… ä Increase of requirements and documentation ä Increase of national control mechanisms

15Q CL Training Seminar, Tanzania | 5-7 December 2007 Global challenges … n National vs international requirements n Number of requirements n Application and interpretation of requirements n Import vs export control on national level n Quality assurance systems applied n Knowledge of product by parties involved in manufacture n Cross-border promotion and sale - Internet n Free trade zones

16Q CL Training Seminar, Tanzania | 5-7 December 2007 Global challenges… n Number of national and international inspections by same party n Number of inspections in same site by different parties n Applicability of new technologies in different settings n Contracts, agreements, eg Mutual Recognition Agreements n Risks of mistakes, accidents, human errors etc n Counterfeit drugs n …...

17Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s global guidelines and strategies n Requirements for drug registration and model legislation n Networking among and with regulatory authorities n International alerts n Counterfeit network n Global norms and international standards and nomenclature

18Q CL Training Seminar, Tanzania | 5-7 December 2007 INNs

19Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s medicines quality assurance guidelines Cover: n Production n Quality Control n Quality related regulatory guidelines n Inspection n Distribution n  from manufacture to delivery to patient

20Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s global guidelines - quality control - ä International specifications (Ph. Int., screening tests..) ä WHO Model Certificate of Analysis (COA) ä Considerations for requesting analysis of samples ä Quality control laboratories:  Good practices for national control labs  List of equipment  External qc assessment scheme for labs

21Q CL Training Seminar, Tanzania | 5-7 December 2007 International Pharmacopoeia  current: 4 th edition! Supplement 1 in preparation  implementation: “ready for use” by Member States  Scope since 1975:  Model List of Essential Medicines and  Drugs recommended by WHO Specific disease programmes, e.g. Malaria, TB, HIV/AIDS

22Q CL Training Seminar, Tanzania | 5-7 December 2007

23Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s strategy for quality control  Step-wise approach: - Basic tests (identification) - Screening tests (TLC) - The International Pharmacopoeia + International chemical reference standards (ICRS) + IR reference spectra

24Q CL Training Seminar, Tanzania | 5-7 December 2007 External Quality Assessment Scheme for National Drug Quality Control Laboratories  Capacity building  Third phase  Series of 5 tests  42 participating laboratories, including WHO Collaborating Centres  In all 6 WHO regions

25Q CL Training Seminar, Tanzania | 5-7 December 2007 External Quality Assessment Scheme for National Drug Quality Control Laboratories n Phase 4 (06/ /2009) - 50 laboratories invited to participate. - Studies: ä Titration ä Water content by Karl-Fisher ä Dissolution test ä Determination of glucose by polarimetry ä HPLC assay

26Q CL Training Seminar, Tanzania | 5-7 December 2007 Participation in External Quality Assurance Scheme -> link with PQ Programme n Phase 3 (07/ /2006) ä 11 of QC laboratories involved in prequalification procedure participated l Algeria, South Africa CENQAM, South Africa RIIP l Ghana, Kenya, Mali, Niger, Senegal, Tanzania, Uganda, Zimbabwe ä 2 other African QC laboratories took part l Morocco, Tunisia n Phase 4 (06/ /2009) ä All 15 QC laboratories involved in prequalification procedure invited

27Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s global guidelines - distribution  WHO Certification Scheme for Pharmaceutical Products Moving in International Commerce  SMACS new scheme for pharmaceutical starting materials:  - Model certificate, when inspected by national authority  - Model for self-assessment for manufacture of pharmaceutical starting materials

28Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s global guidelines – distribution (2) n Good Distribution and Trading Practices for pharmaceutical starting materials (GTDP) n Good Distribution Practices (GDP) (for products) n Good Storage Practices (GSP)

29Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s global guidelines -production n Good Manufacturing Practices (GMP) ….. n 1. Main principles for pharmaceutical products n 2. … for starting materials, including ä active pharmaceutical ingredients ä pharmaceutical excipients n 3. … for specific pharmaceutical products: ä Sterile pharmaceutical products ä Biological products ä Investigational pharmaceutical products for clinical trials in humans ä Herbal medicines ä Radiopharmaceuticals

30Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s global guidelines -production (2) n Newly revised and additional GMP texts: n 1. Main principles for pharmaceutical products +++ ä requirement for the sampling of starting materials (amendment) ä water for pharmaceutical use ä heating, ventilation and air-conditioning (HVAC) systems ä Validation n 3. … for specific pharmaceutical products: +++ ä Herbal medicines (revised)

31Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s global guidelines - inspection n Inspection of….. ä pharmaceutical manufacturers ä drug distribution channels (products) n Guidelines for pre-approval inspection n Quality systems requirements for national GMP inspectorates n Model GMP certificate n Model report for inspections

32Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s global guidelines and strategies - risk analysis n Application of risk analysis to production of pharmaceuticals ( adopted in 2001)

33Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO stability guidelines n Title: “guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms” currently under revision ! n -> stability testing of final drug products n -> well established (e.g. generics) n -> in conventional dosage forms (e.g. tablets) n --> close collaboration with ICH group Q1, ASEAN, GCC and other regional harmonization groups

34Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO Stability guidelines second draft What's new? n Scope covers: active pharmaceutical ingredients + pharmaceutical products n Marketed + new n Transition period recommended for already marketed actives and products n Additional advice given, e.g. model reports currently used in WHO Prequalification Programme

35Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO Stability guidelines second draft What's new? (2) n Cross-reference to other guidelines, e.g. ICH text on photostability n List of WHO Member States' required long-term stability conditions as per info received from countries, concept of classification of countries according to climatic zones abandoned -> preference to provide "real" conditions required by national authorities

36Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s guidance on interchangeability of medicines n WHO guideline on registration requirements to established interchangeability for multisource pharmaceutical products (newly revised 2006) n Guidance on selection of comparator products for equivalence assessment of interchangeable generic products (under revision)

37Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s guidance on interchangeability of medicines (2) n Proposal to waive in vivo bioequivalence requirements for the WHO model List of Essential Medicines (immediate release, solid dosage forms) n Guidelines for organizations performing in vivo bioequivalence studies

38Q CL Training Seminar, Tanzania | 5-7 December 2007 Related WHO’s guidances … n All guidelines for Prequalification of medicines, laboratories ….. n Model Quality Assurance System for Assessment of Procurement Agencies n Guideline for sampling of pharmaceuticals n Guidelines for registration of fixed-dose combination medicinal products n....

39Q CL Training Seminar, Tanzania | 5-7 December 2007 Advantages of WHO's Expert Committee standard-setting process n 1. Guidelines and specifications validated internationally, through an independent scientific process, adoption by members of WHO Expert Advisory Panels n 2. Collaboration with standard-setting organizations and parties, including regional and national pharmacopoeias n 3. Networking and close collaboration with WHO Member States, Drug Regulatory Authorities, national medicines quality control laboratories

40Q CL Training Seminar, Tanzania | 5-7 December 2007 Advantages of WHO's Expert Committee standard-setting process (2) n 4. Links with other WHO activities n 5. Reality check: Input from manufacturers (including international associations of research, generic and self-medication associations) around the world n 6. Consideration of costs, e.g. keeping need for reference standards at a minimum n 7. Service FREE FOR USE by all Member States

41Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s operational strategies n Assist Member States to strengthen or establish national drug regulation (upon request) n Study alternative ways of improving control and safe trade of starting materials and products n Promote cooperation and harmonization among countries (e.g. ICDRA) n Collaborate with regional and inter-regional regulatory harmonization efforts (in all 6 WHO regions)

42Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO’s operational strategies -2-  Work with interested parties and countries to combat counterfeit and substandard drugs (IMPACT)  Assistance in establishing and evaluation of national and regional quality control laboratories  Training of drug regulatory staff (e.g. in registration of HIV/AIDS medicines)  Development of “how to” manuals and tools  Responding to national and international requests in area of quality assurance for medicines (e.g. for Global Fund)

43Q CL Training Seminar, Tanzania | 5-7 December 2007 As health professionals, in public and private sector, as an international community...we have a lot left to do …all of us, together, things that do matter, in right time and in right order!

44Q CL Training Seminar, Tanzania | 5-7 December 2007 WHO Medicines Quality Assurance website: assurance